Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2011

View Archived Issues

Summit presents preclinical data on antimicrobial agents targeting CDI

Final first-in-human data presented on CureVac's prostate cancer mRNA vaccine

Horizon Pharma submits NDA for Lodotra to FDA

BioDelivery Sciences reports preliminary data from BEMA Buprenorphine trial

Canadian university discloses novel Abeta-targeted antibodies

Amira Pharmaceuticals patents new 5-LO inhibitors

Advanced Cell Technology receives approval to treat more patients in two U.S. stem cell trials

Scientists identify SNP associated with increased susceptibility to bacterial meningitis

Bacterial DNA minor groove binder shows promise against CDI-associated diarrhea

Eisai evaluates new anticoagulants in human microdosing study

Japanese Pharmaceutical Affairs Subcommittee reviews Chugai's application for Epogin

Dosing begins in Trius' phase III TR701-113 trial

FDA reviews safety of drospirenone-containing birth control pills

Novel anticancer derivatives presented

Boehringer Ingelheim Pharma claims new therapeutics targeting amyloid beta

GlaxoSmithKline reports new SAP-binding proteins

Pharmaxis completes enrollment in phase II ASM-8 trial

Durata Therapeutics begins enrollment in second pivotal dalbavancin trial

Children's Oncology Group and Apeiron to collaborate on phase II study in neuroblastoma

Proteonomix continues preparations for clinical trial of stem cell treatment for ESLD

Almirall launches Libertek in Spain

Microbicide Trials Network to discontinue use of tenofovir tablets in HIV prevention study

Baxter files MAA with EMA for investigational Ig therapy

Formal Medicare coverage policy established for Genomic Health's Oncotype DX colon cancer test

Takeda completes Nycomed acquisition

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...